Antheia, a biosynthesis company delivering pharmaceutical manufacturing and innovation, has expanded the scope of its second project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), securing an additional $9 million. The additional funds bring the total project investment to $21 million directly supporting the company’s efforts to build resilient, domestic pharmaceutical supply chains. 

The award, funded by the U.S. Department of Health and Human Services’ (HHS) Defense Production Act (DPA) Title III Program, serves as continued validation of the federal government’s commitment to onshoring pharmaceutical supply chains. Through the expanded agreement, Antheia will leverage its advanced biosynthesis platform to domestically produce two critical pharmaceutical ingredients at a significantly increased commercial scale. 

“We value the opportunity to deepen our collaboration with the U.S. government and help address longstanding supply chain vulnerabilities affecting U.S. healthcare systems and the American people,” said Dr. Christina Smolke, CEO and co-founder of Antheia. “In working with the BioMaP-Consortium, we aim to support the ongoing efforts to strengthen national and public health security.”